InSyBio makes the big step to the USA biotechnology market with the help of International Accelerator!

InSyBio is the latest startup company to join the International Accelerator program in Austin, Texas USA ( with an ultimate goal to get access to the USA biotechnology market.

Labros Digonis, the CEO of InSyBio, who holds a MBA and Master’s Degree in Naval Architecture & Marine Engineering and has over 30 years of experience in top-management positions in multibillion groups and as management consultant in several Industries, stated about InSyBio’s collaboration with the International Accelerator that “We don’t only share common interests but the same vision and passion which trancends a common partnership; it’s a strategic alliance to create something great to not only serve America but the World!”

InSyBio joined IA’s program to expand their operations in North America, as well as gain access to institutional investors to expedite their growth. IA’s program is unique as they invest exclusively in foreign-born entrepreneurs. The 12-month customized program is designed for portfolio companies to gain access to the U.S. market and secure venture capital funding for growth opportunities. In addition, each portfolio companies receives a hand selected mentor, a deep dive strategic and operational roadmap to success, 12-months of free working space, $50,000 in seed funding, and a host of other value-add services.

About InSyBio: InSyBio is a privately held, global bioinformatics company ( focusing, through advanced biological big-data computational tools, on biomarkers discovery for Cancer, Neurodegenerative diseases and Nutrition. Biomarker extraction from biological big data (genomics, transcriptomics, proteomics, etc.) is essential for drug discovery & research acceleration, personalized medicine and Nutrition.

InSyBio’s patented breakthrough technology offers unique inside path to an integrated end-to-end accurate biomarker discovery process, simultaneous integration of data from different sources and types and has demonstrated ability to locate significantly more common proteins in large scale proteomics datasets. At InSyBio, the team is passionate about supporting customers to minimize their efforts, as they design and develop new drugs, therapeutic and diagnostic methods.

About International Accelerator: The International Accelerator is the only U.S. accelerator focused solely on investing in companies with non-U.S. citizen founders. IA provides access to seed funding, quality mentors, and services foreign-born entrepreneurs need to scale up their businesses in the United States. The International Accelerator is more than an accelerator program. It is a trusted co-founder for stateside ventures and dedicated to helping non-U.S. citizen entrepreneurs set up their U.S. company, give it an “American look and feel,” and lay a sturdy foundation to build a global business. The experienced team leverages years of international business, design, and entrepreneurial expertise, as well as access to industry experts, active investors and potential customers. At IA, the goal is to bring startups in and send them out with impressive products and the capability to stand on their own feet. Being entrepreneurs themselves, they clearly know the hardships and worries of the startup process. Apart from money, IA is always available to give the help customized for the founder, so they can focus on their product and developing their vision for the company.

For more News visit our InSyBio Blog.

InSyBio wins the Investor Prize in the category of Big Data for Health in Sanofi’s Labs in the VivaTech 2017 event

We are proud to announce that InSyBio is the winner of the Investor Prize in the category of Big Data for Health in Sanofi’s “Tech for health” Lab in VivaTech 2017 event ( which was held at Paris, 15-17 June, 2017.

InSyBio was one of the 34 innovative companies sponsored by Sanofi to join the Viva Technology 2017 event. In this event, we presented our biomarker discovery platform (InSyBio Suite) as a solution able to be a catalyst in accelerating Pharma clinical trials being achieved through the identification of key predictive biomarkers for i) drug toxicity and disease progression and ii) drug efficacy.

By winning the Investor’s prize InSyBio was given with the opportunity to discuss with top executives of Sanofi for a potential investment in our company, while is now in close contact with various Sanofi’s R&D departments to explore the applicability of InSyBio’s solution in various clinical trials and data analytics research projects of Sanofi around the world.

InSyBio’s experience in the VivaTech Event was exciting and gave our scientists the opportunity to get in touch with the pharma, nutrition and cosmetics ecosystems and industrial clusters in France. Additionally, several collaborations have been initiated with French IT and biotechnology companies for co-development and co-selling activities while InSyBio have also found strong interest from investors for the participation to its current Series A financing round.

InSyBio’s participation in the VivaTech 2017 event was supported by the French Embassy in Greece/ French Institute of Greece and the “Mazinnov” project, French Embassy’s initiative for the creation of bridges between Greek and French innovation ecosystems.

About InSyBio: InSyBio is a bioinformatics pioneer company in personalized healthcare which focuses on developing computational frameworks and tools for the analysis of complex life-science and biological data, aiming at the discovery of predictive integrated biomarkers (biomarkers of various categories) with applications in pharma, nutrition and cosmetics industries.

Find more details at .

For more News visit our InSyBio Blog.

Posts navigation

1 2 3
Scroll to top